We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $980M
1-Year Est. Return 470.8%
This Fund
S&P 500
This Quarter Est. Return
+1.21%
1 Year Est. Return
+470.8%
3 Year Est. Return
+3,352.06%
5 Year Est. Return
+7,957.7%
10 Year Est. Return
–
AUM
$224K
AUM Growth
-$183M
Cap. Flow
+$30.6M
Cap. Flow %
13,629.74%
Top 10 Hldgs %
33.66%
Holding
127
New
36
Increased
38
Reduced
22
Closed
31

Top Buys

Rank Stock Value
1
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$5.26M
2
MGNX icon
MacroGenics
MGNX
+$5.18M
3
ELOX
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
+$3.94M
4
VCYT icon
Veracyte
VCYT
+$3.89M
5
MSAC
Medicus Sciences Acquisition Corp. Class A Ordinary Share
MSAC
+$3.65M

Top Sells

Rank Stock Value
1
VCEL icon
Vericel Corp
VCEL
+$6.78M
2
CRIS icon
Curis
CRIS
+$4.17M
3
MSACU
Medicus Sciences Acquisition Corp. Unit
MSACU
+$4.01M
4
ACRS icon
Aclaris Therapeutics
ACRS
+$3.36M
5
LRMR icon
Larimar Therapeutics
LRMR
+$2.8M

Sector Composition

Rank Sector Weight
1 Healthcare 79.44%
2 Financials 6.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SNDX icon
76
Syndax Pharmaceuticals
SNDX
$1.74B
$596 0.27%
34,727
+14,727
+74% +$270K
GH icon
77
Guardant Health
GH
$19B
$580 0.26%
4,673
-5,519
-54% -$742K
CERS icon
78
Cerus
CERS
$585M
$528 0.24%
+18,691
New +$110K
SAGE
79
CALL
DELISTED
Sage Therapeutics
SAGE
$528 0.24%
9,300
-10,700
-54% -$756K
ETNB
80
DELISTED
89bio
ETNB
$524 0.23%
28,032
-21,975
-44% -$491K
VRDN icon
81
Viridian Therapeutics
VRDN
$2.15B
$519 0.23%
28,399
+813
+3% +$13.9K
DCOY
82
Decoy Therapeutics
DCOY
$2.15M
$500 0.22%
13
-42
-76% -$1.87M
RCKT icon
83
Rocket Pharmaceuticals
RCKT
$343M
$456 0.2%
10,293
+293
+3% +$12.7K
APLS
84
DELISTED
Apellis Pharmaceuticals
APLS
$443 0.2%
+7,009
New +$362K
ATXS
85
DELISTED
Astria Therapeutics
ATXS
$398 0.18%
+31,463
New +$409K
KALV
86
DELISTED
KalVista Pharmaceuticals
KALV
$357 0.16%
14,882
-35,118
-70% -$919K
MDNA
87
DELISTED
Medicenna Therapeutics Corp. Common Shares
MDNA
$333 0.15%
110,515
+2,979
+3% +$11K
QURE icon
88
uniQure
QURE
$2.52B
$288 0.13%
+9,346
New +$313K
MDGL icon
89
Madrigal Pharmaceuticals
MDGL
$12.4B
$242 0.11%
+2,480
New +$294K
FMTX
90
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$241 0.11%
+9,679
New +$260K
AYLA
91
DELISTED
Ayala Pharmaceuticals, Inc. Common Stock
AYLA
$238 0.11%
+23,364
New +$240K
ETON icon
92
Eton Pharmaceutcials
ETON
$1.28B
$115 0.05%
+18,691
New +$138K
CHAQ.WS
93
DELISTED
Chardan Healthcare Acquisition 2 Corp. Warrants, entitling the holder thereof to purchase one-half (
CHAQ.WS
$85 0.04%
104,828
+6,072
+6% +$4.35K
PHGE icon
94
BiomX
PHGE
$1.98M
$78 0.03%
75
+3
+4% +$3.49K
CALA
95
DELISTED
Calithera Biosciences, Inc
CALA
$66 0.03%
1,569
+69
+5% +$3.03K
MSACW
96
DELISTED
Medicus Sciences Acquisition Corp. Warrant
MSACW
$50 0.02%
+49,990
New +$39.6K
ARVN icon
97
Arvinas
ARVN
$529M
– –
-25,071
Closed -$1.66M
ATNM icon
98
Actinium Pharmaceuticals
ATNM
$27.2M
– –
-45,910
Closed -$350K
BDTX icon
99
Black Diamond Therapeutics
BDTX
$101M
– –
-6,000
Closed -$146K
BIIB icon
100
CALL
Biogen
BIIB
$30.4B
– –
-10,000
Closed -$2.8M
2 3
4
5 6

Similar funds

BIP
Blueprint Investment Partners Greensboro, North Carolina $980M AUM 27.19% 1-Year Est. Return
EWA
Evolution Wealth Advisors Aventura, Florida $981M AUM 21.2% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return
MFWP
Mosaic Family Wealth Partners St. Louis, Missouri $977M AUM 19.09% 1-Year Est. Return
FCM
Fortis Capital Management Bellevue, Washington $977M AUM 17.17% 1-Year Est. Return
PE
PSG Equity Boston, Massachusetts $977M AUM 13.39% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
GFP
Gryphon Financial Partners Columbus, Ohio $976M AUM 23.05% 1-Year Est. Return

Silverarc Capital Management's Q2 2021 Portfolio in Review

As of Q2 2021, Silverarc Capital Management held 127 positions worth $224K, down 100% from $183M the previous quarter. Its ten largest holdings account for 34% of the portfolio.

Silverarc Capital Management deployed $30.6M of net new capital in Q2 2021, opening 36 new positions and adding to 38 existing holdings. Its largest new stake was MacroGenics: 176,915 shares worth $4.75K.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 86% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Curis, an estimated $4.17M trimmed.

  • Silverarc Capital Management's largest Q2 2021 buy was MacroGenics: 176,915 shares worth $4.75K.
  • Silverarc Capital Management added most to Mirati Therapeutics, Inc. Common Stock in Q2 2021, an estimated $5.26M increase.
  • Silverarc Capital Management's biggest Q2 2021 reduction was Curis, cutting an estimated $4.17M.
  • Silverarc Capital Management fully exited Vericel Corp in Q2 2021, selling an estimated $6.78M.
  • Silverarc Capital Management's ten largest holdings make up 34% of its $224K portfolio in Q2 2021.
  • Silverarc Capital Management opened 36 new positions and closed 31 in Q2 2021.
  • Silverarc Capital Management's portfolio value fell 100% quarter-over-quarter to $224K.

Based on Silverarc Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.